These preclinical findings paved the way for phase III clinical studies testing the PI3Kα inhibitor alpelisib with fulvestrant in patients with metastatic PIK3CA-mutant ER+ breast cancer and culminated in the approval of alpelisib by the Food and Drug Administration (FDA) in 2019 (4). This evidence concerns the gene PIK3CA and breast cancer.